Freedom of Information request on breakdown by age for other types of ADR similarly to Thrombo-Embolic events (FOI 21-669)
Updated 27 April 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-12-july-2021/freedom-of-information-request-on-breakdown-by-age-for-other-types-of-adr-similarly-to-thrombo-embolic-events-foi-21-669
14th July 2021 FOI 21/669
Dear
Thank you for your email dated 15th June 2021, where you requested the following: “I note that the only ADR you break down by age is for Thrombo-Embolic events. Can you release information similar to Table 5 on this page, to the same level of granularity for the other types of ADR please.”
The MHRA intends to publish all suspected reactions reported in association with available COVID-19 vaccines in an interactive format as interactive Drug Analysis Profiles (iDAPs), along with our ADR summary that is published each week. The use of iDAPs will enable users to view the data by categories of their choice such as age, sex and seriousness of reports. Users will also be able to download the data tables in CSV format.
As we plan to publish the data, we consider that your request is covered by Section 22 of the Freedom of Information Act (information intended for future publication) and the information you have asked for is therefore exempt from disclosure. Section 22 is a qualified exemption which means we have considered whether there is a greater public interest in releasing the information requested or withholding it. We recognise there is strong interest in seeing this data and accept it should not be withheld however wish to publish this information alongside appropriate context and assessment.
We will send you a link to the iDAPs once they are published.
I hope the information provided and explanation regarding the exemption is helpful. If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review will be carried out by a senior member of the Agency who was not involved with the original decision.
Yours sincerely, FOI Team Vigilance and Risk Management of Medicines Division